Triple therapy trial aims to ease rare lung disease
Disease control
Not yet recruiting
This study tests whether a combination of three drugs (an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, and sotatercept) can improve blood flow in the lungs of people newly diagnosed with pulmonary arterial hypertension (PAH). 25 adults aged 18-70 will receive …
Phase: PHASE2 • Sponsor: Philipps University Marburg • Aim: Disease control
Last updated May 06, 2026 16:00 UTC